← Back
$ACAD All transactions

ACADIA PHARMACEUTICALS INC

M 10b5-1 Plan

$ Value

$0

Shares

6,178

Price

$0

Filed

Mar 26

Insider

Name

Schneyer Mark C.

Title

EVP, CHIEF FINANCIAL OFFICER

CIK

0001899977

Roles

Officer

Transaction Details

Transaction Date

2026-03-25

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

12,358

Footnotes

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. | The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). | The restricted stock units vest in four equal annual installments beginning March 24, 2026. | The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Filing Info

Accession No.

0001899977-26-000003

Form Type

4

Issuer CIK

0001070494

Schneyer Mark C.'s History

Date Ticker Type Value
2026-04-07 ACAD $60K
2026-04-05 ACAD M
2026-04-05 ACAD M $0
2026-03-26 ACAD $69K
2026-03-26 ACAD $804
2026-03-25 ACAD $90K
2026-03-25 ACAD M
2026-03-25 ACAD M $0
2026-03-24 ACAD M
2026-03-24 ACAD M $0

Other Insiders at ACAD (90d)

Insider Bought Sold Last
Rhodes Jennifer J
EVP, CHIEF LEGAL OFFICER, SEC
$83K 2026-03-25
Kihara James
PRINCIPAL ACCOUNTING OFFICER
$65K 2026-04-07
Owen Adams Catherine
Chief Executive Officer
$250K 2026-03-25
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev
$74K 2026-03-25
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
$219K 2026-04-07